DEMO Pharmaceuticals S.A.

Who are we?
Efarmes is a generic pharmaceutical company devoted to develop and manufacture generics for third parties all over the world. Efarmes Generics Company is part of Lacer Group. Our head offices, manufacturing site with EU cGMP’s and R&D area are in Barcelona.

What we do?
Efarmes Generics Company seeks partners that want to in-license and market the generics. Our partners are both multinational and local pharmaceutical companies on the five continents. Efarmes Generics Company offers tailored-made proposals such as full development and manufacturing of generic pharmaceutical products ready to be marketed by third parties under their own brand name, co-development of generic products, and contract manufacturing.

How we do it?
Efarmes Generics Company covers all levels from formulation to finished product delivery. Efarmes Generics Company currently supplies finished dosage forms to many key players all over the world. Our manufacturing site plant produced last year 24 M units (3.240 batches) with 99,9% Quality Control Conforming.

Our Business Proposal
Our main business model is the out license and supply of generic finished dosage forms. Our dossiers are in EU CTD format and ready to file. We have some MAs available in Europe.

Dossiers ready to file:
- Rasagiline (Parkinson’s diseases)
- Alprazolam (Anxiolytic)
- Deflazacort (Corticosteroid)
- Modafinil (Narcolepsy)
- Sildenafil (Erectil Dysfunction)
- Pioglitazone (Diabetes)
- Rivastigmine (Alzheimer diseases)

Dossiers under development:
- Olmersartan + Amlodipine + Hidroclorothiazide (Hypertension). Q2 2016 Bioequivalence studies on-going.
- Tapentadol, retard tabs, (Neurophatic Pain). Dossier will be available in 2018.

Products which are subject to patent are currently not offered or made available in countries where patents are in force. No orders or deliveries prior to the expiry date of valid patents are possible.

Please, contact us on generics@efarmes.es

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins.

With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids.

CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, viral vaccines and exosomes.

With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.

FinVector is a world leader in R&D and cGMP manufacturing of Viral-Based Gene Therapy products. Our state-of-the-art facilities, highly experienced scientific team and commitment to work closely with clients every step of the way, have helped us to build an excellent reputation in the gene therapy market. We are authorised under EMA for the production of gene therapy products for clinical and commercial supply.

We offer services across a wide range of viral-based product types, including Adenoviral, AAV, and Lentiviral-based vectors. From our cutting-edge fully-licensed GMP manufacturing facility in Finland, we have built an extensive pipeline of gene therapy products and technologies for our clients. Find out more about our services by visiting our webpage.

Our mission is to improve and extend people's lives by finding solutions in advanced medicines.

Moreover, we want to be a company that people aspire to work for. FinVector is a lively and international working community with a wide range of career opportunities. We currently employ over 250 employees from 19 different countries.

Since December 2014, the new Reig Jofre is the pharma company resulting from the merger between Laboratorio Reig Jofre SA and the publicly traded company Natraceutical SA, which resulted in the fifth Spanish pharma company listed on the stock exchange (ticker: RJF).

Reig Jofre directs its activity to the research, development, manufacturing and marketing of medicines and food supplements, as well as to the specialized manufacturing for third-parties. The company focuses its R&D on the development of new indications and/or dosage forms of known active principles, generics with special focus on beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and nutritional supplements, as well as on the development of innovative molecules in partnership with start-ups and research centers.

For further information, visit our website.

A first-class contract development and manufacturing organization (CDMO), Rottendorf Pharma has been manufacturing, packaging, developing formulations and analytical methods for solid oral dosage forms for the global pharmaceutical industry for more than 85 years. The company produces more than 600 originator and generic drug products annually for big, small, virtual, and global pharmaceutical and biotechnology companies.

Rottendorf Pharma operates by the philosophy of Total Process Ownership (TPO) and Total Technological Mastering (TTM), in which we work as an extension of clients'​ organizations. Therefore leveraging our expertise to optimize solid dosage form production for our customers'​ benefit. Rottendorf Pharma has neither their own product brands in the market nor holds any product licenses, and therefore is never in competition with their clients.